Lilly's CYRAMZA (ramucirumab) significantly improved overall survival in phase 3 non-small cell lung cancer study. Results from the REVEL trial were published in The Lancet and also presented at ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback